|
|
Gene Symbol |
NAMPT |
|
Aliases |
1110035O14Rik, PBEF, PBEF1, VF, VISFATIN |
|
Entrez Gene ID |
|
|
Gene Name |
Nicotinamide phosphoribosyltransferase |
|
Chromosomal Location |
7q22.3 |
|
HGNC ID |
|
|
Summary |
This gene encodes a protein that catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein belongs to the nicotinic acid phosphoribosyltransferase (NAPRTase) family and is thought to be involved in many important biological processes, including metabolism, stress response and aging. This gene has a pseudogene on chromosome 10. [provided by RefSeq, Feb 2011]
|
|
e!Ensembl
|
Protein Information |
|
Protein Name |
Nicotinamide phosphoribosyltransferase, NAmPRTase, pre-B cell-enhancing factor, pre-B-cell colony-enhancing factor 1 |
|
Function |
Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma. Plays a role in the modulation of circadian clock function. NAMPT-dependent oscillatory production of NAD regulates oscillation of clock target gene expression by releasing the core clock component: CLOCK-ARNTL/BMAL1 heterodimer from NAD-dependent SIRT1-mediated suppression (By similarity). |
|
|
UniProt |
|
|
PDB |
2E5B, 2E5C, 2E5D, 2GVG, 2GVJ, 3DGR, 3DHD, 3DHF, 3DKJ, 3DKL, 4JNM, 4JR5, 4KFN, 4KFO, 4KFP, 4L4L, 4L4M, 4LTS, 4LV9, 4LVA, 4LVB, 4LVD, 4LVF, 4LVG, 4LWW, 4M6P, 4M6Q, 4N9B, 4N9C, 4N9D, 4N9E, 4O0Z, 4O10, 4O12, 4O13, 4O14, 4O15, 4O16, 4O17, 4O18, 4O19, 4O1A, 4O1B, 4O1C, 4O1D, 4O28, 4WQ6, 5KIT, 5LX3, 5LX5, 5NSD, |
|
Pfam |
Pfam Accession |
Pfam ID |
PF04095 |
NAPRTase |
|
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000470498 |
Q75N90 |
Q75N90 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Digestive System Diseases |
Colitis |
|
Endocrine System Diseases |
PCOS |
|
Immune System Diseases |
Dermatitis |
|
Neoplasms |
Head Neoplasms |
|
Mouth Neoplasms |
|
Colorectal Cancer |
|
Nutritional and Metabolic Diseases |
Obesity |
|
Gluocose Intolerance |
|
Reproductive disorders |
Preeclampsia |
|
|
References |
|
|
|
PubMed ID |
Associated gene/s |
Associated condition |
Genetic Mutation |
Diagnostic Criteria |
Association with PCOS |
Ethnicity |
Conclusion |
|
PYY,serum adiponectin,sCD40L,GHRL, sP-, sE-selectins, resistin |
Pancreatic islet adaptation to insulin resistance,low-grade chronic inflammation,endothelial dysfunction,atherosclerosis,obesity |
|
Rotterdam criteria |
Related
|
|
The study provides the first evidence that lean untreated young PCOS women contribute to the so called "pancreatic islet adaptation to insulin resistance" because of ghrelin and PYY profiles. We confirmed existing of low-grade chronic inflammation in early stage of visceral obesity in lean PCOS patients. |
|
DHEA-S,17alpha-OH-progesterone,SHBG,PRL,Delta(4)-androstenedione |
Metabolic and hormonal disturbances,obesity |
|
|
Related
|
25 PCOS, 24 overweight controls and 24 controls |
The present study indicates, for the first time, a possible involvement of increased visfatin levels in PCOS-associated metabolic and hormonal disturbances. |
|
Adiponectin and Leptin |
|
|
|
Related
|
73 PCOS and 75 Control |
PCOS have high visfatin and leptin levels but low adiponectin levels |
|
|
PCOS |
|
|
Direct
|
21 PCOS and 15 Controls |
The data indicates that plasma visfatin levels are associated with HDL-C and markers of hyperandrogenism, but it is not associated with proinflammatory markers and insulin resistance in lean women with PCOS |
|
RBP4 |
|
|
|
Related
|
27 PCOS and 19 control |
PCOS have increased circulating visfatin and unaltered RBP4 concentrations compared with healthy lean women |
|
omega-3 fatty acid |
Obesity |
|
|
Related
|
61 PCOS |
beneficial effect was not associated with alteration in anthropometric measurements and serum visfatin levels |
|
|
|
|
|
Related
|
91 PCOS and 28 Control |
serum visfatin is significantly elevated in Chinese women with PCOS, but might not be a reliable predictor of their glucose intolerance |
|
|
|
|
|
Related
|
37 PCOS and 30 Control |
|
|
|
|
|
|
Related
|
South-Korea and Northern Finland (57PCOS and 57 controls ) |
circulating visfatin levels correlate with WBC and CRP but are not associated with PCOS, obesity or metabolic markers |
|
|
|
|
Rotterdam criteria |
Related
|
10 PCOS and 10 controls |
PCOS is associated with increased visfatin mRNA concentrations in PBMCs and in omental adipose tissue |
|
|
Endothelium dysfunction |
|
|
Related
|
69 PCOS and 33 controls |
Visfatin may be a candidate to play a role in the pathogenesis of endothelial dysfunction in PCOS |
|
|
|
|
|
Related
|
55 PCOS and 49 Control |
Visfatin levels in obese and overweight patients with PCOS were higher than that found in females without concomitant disease |
|
|
|
|
|
Related
|
40 PCOS and 40 control |
Asian PCOS women had significantly higher serum visfatin levels than age-matched healthy controls |
|
RBP4 |
|
|
|
Related
|
83 PCOS and 67 control |
Plasma visfatin level is not a useful biomarker of insulin resistance and hyperandrogenism |
|
|
cardiovascular disease |
|
Rotterdam criteria |
Related
|
200 PCOS and 100 controls |
VF amount is associated with subclinical CVD in PCOS patients |
|
|
Hyperandrogenism |
|
Rotterdam criteria |
Related
|
70 PCOS and 45 Control |
Visfatin is associated with insulin resistance and markers of hyperandrogenism in lean PCOS patients |
|
|
|
|
Rotterdam criteria |
Related
|
26 PCOS and 26 control |
PCOS exhibit higher plasma visfatin levels than control subjects of similar body mass index |
|
|
|
|
Rotterdam criteria |
Related
|
8 PCOS, * controls |
Up-regulation of visfatin seen in women with PCOS |
|
|
|
|